Veterinary Professional Development (VetPD) will convene a panel discussion on new intra-articular non-biologic joint medications and therapies including 2.5% polyacrylamide hydrogel, Arthramid® Vet on June 8, 2021. The 3 hour panel discussion will begin at 2:00 p.m. eastern time and will be recorded.
Learn about Arthramid® Vet from a panel of internationally renowned equine practitioners, sports medicine specialists & surgeons. The panel will discuss results from recently published studies along with clinical experience in managing osteo-arthritis in horses with polyacrylamide hydrogels including Arthramid® Vet. Panelists will include Florent David DVM, MS, Dipl. ACVS, Dipl. ECVS, Dipl. ACVSMR, ECVDI European & American Specialist in Equine Surgery; European Specialist in Diagnostic Imaging and American Specialist in Equine Sports Medicine/Rehabilitation Doha, Qatar; Scott McClure DVM, PhD, Dipl. ACVS, Dipl. ACVSMR American Specialist in Equine Surgery; American Specialist in Equine Sports Medicine. United States; Ben Ahern BVSc (Hons I) PhD MACVSc Dipl. ACVS Dip. ACVSMR, Section Head, Equine Specialist Hospital. Australia. Heidi Reesink VMD, PhD, DACVS-LA will serve as the moderator.
In November 2020, ConturaVet, manufacturer of Arthramid® Vet launched the product in the United States. Arthramid® Vet 2.5% polyacrylamide hydrogel is labeled for intra-articular administration for the management of all stages of OA & DJD in horses in the USA.
Arthramid® Vet hydrogel products are developed and produced in our state-of-the-art FDA-approved GMP manufacturing facility in Denmark. Knowing how important quality of manufacturing is to veterinarians, this makes Arthramid® Vet the safe choice for your patients.
Arthramid® Vet is produced by a patented technology called In-line Cross-Linking Technology, which forces water molecules between the cross-linked polymers of polyacrylamide. This gives the hydrogel a unique molecular stability and the ability to retain its viscoelastic properties. It is non-toxic, neuro-innocuous and maintains its viscoelasticity over time.
Arthramid® Vet’s 2.5% PAAG is hydrophilic with lightly bound water molecules that can interchange with water molecules of surrounding synovial tissues. After administration, branching of the polyacrylamide chains takes place, and a three-dimensional matrix of cross-linked polyacrylamide is formed. The Arthramid® Vet matrix formed is less rigid than other PAAG scaffolds. Unique to Arthramid® Vet, the scaffold maintains uniform porosity allowing an ideal level of tissue integration and vessel ingrowth into the hydrogel matrix. This provides more stability for tissue ingrowth whereby creating a permanent scaffold that is integrated into the synovial tissue.
Arthramid® Vet contains no impurities, does not become encapsulated, has the most compatible pH range of all PAAG’s and is permanently stable.
Attendance is $65 for veterinarians. ConturaVet will reimburse current Arthramid® Vet customers their attendance fee to this meeting. Send your receipt to: firstname.lastname@example.org.
Visit VetPD.com to learn more.
For more information about Arthramid® Vet, please contact Nicola Woods at ConturaVet Nicola@conturavet.com Phone: +44 (0) 845 862 3292